Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Most relevant
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about EISAI CO., LTD.
10/21BIOARCTIC : Interim Report for the period July - September 2021
AQ
10/18Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University
CI
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
AQ
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
PU
10/15Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
DJ
09/29EISAI CO., LTD. : Ex-dividend day for interim dividend
FA
09/28EISAI : Starts Rolling Submission To Seek US Approval For Alzheimer's Disease Therapy
MT
09/27EISAI : INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF ..
PU
09/27BIOARCTIC : Eisai initiates rolling submission for the US FDA Biologics license applicatio..
AQ
09/27BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics Lice..
CI
09/27Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of..
CI
09/27EISAI : Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
AQ
09/27EISAI : Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approva..
PU
09/22EISAI : Italy awarded highest classification at sixth annual welfare index pmi* in italy
PU
09/21EISAI : Latest Value Creation Report (Former Integrated Report)
PU
09/15EISAI : To join the global emvironmental initiative 're100'
AQ
09/14EISAI : AbbVie, Eisai, and EA Pharma Launch 'Humira Support Tool Ordering Service for Pati..
AQ
09/14EISAI : to Join The Global Environmental Initiative "RE100"
AQ
09/14EISAI : TO JOIN THE GLOBAL EMVIRONMENTAL INITIATIVE “RE100”
PU
09/13EISAI : To present abstracts on oncology products and pipeline at esmo virtual congress 20..
PU
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Pati..
AQ
09/13EISAI : AbbVie, Eisai, and EA Pharma Launch “Humira® Support Tool Ordering Service f..
PU
09/10Japan's Nikkei 225 Up 1.3% on Outlook for Expanded Government Stimulus
MT
09/10Japan's Topix hits highest since 1990 on hopes of new govt, better earnings
RE
09/09Japan shares rally on, Topix hits over 30-year high on earnings optimism
RE
09/09Neuroglee Therapeutics Pte. Ltd. announced that it has received $10 million in funding ..
CI
09/07CITIUS PHARMACEUTICALS : Acquires Rights to Oncology Immunotherapy E7777 From Dr. Reddy's ..
MT
08/30EISAI : and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distrib..
PU
08/30BIOGEN : provides free Aduhelm as U.S. clinics await Medicare payment
RE
08/15EISAI : Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in ..
AQ
08/12MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combination for Fi..
AQ
08/11EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Fi..
AQ
08/11EISAI : FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination for ..
PU
08/05EISAI : Notification Regarding Revision of Consolidated Financial Forecasts for the Fiscal..
AQ
08/04EISAI : Receives award for excellence in corporate communications at the 37th corporate co..
PU
08/03EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the..
PU
08/03EISAI : FY 2021 (Ending March 31, 2022) First Quarter Financial Results Reference Data
PU
08/03EISAI : CONSOLIDATED FINANCIAL REPORT for the Three-Month Period Ended June 30, 2021
PU
08/03Eisai Co., Ltd. Reports Consolidated Financial Results for the Three Months Period Ende..
CI
08/03Eisai Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022
CI
08/03Eisai Co., Ltd. Provides Dividend Guidance for the Second Quarter and the Fiscal Year 2..
CI
08/02BIOGEN : and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Obse..
AQ
08/02BIOGEN : Eisai Co., Ltd. - LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFF..
AQ
08/02EISAI : Anti-epileptic drug fycompa approved in china as monotherapy for partial-onset sei..
AQ
08/02EISAI : Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Sei..
AQ
08/01EISAI : Anti-epileptic drug fycompa® approved in china as monotherapy for partial-onset se..
PU
07/30EISAI : LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFFECTS OF LECANEMAB (..
PU
07/30BIOARCTIC : Eisai presented latest data from the lecanemab clinical program at AAIC 2021
AQ
07/29EISAI : and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BA..
AQ
07/29EISAI : Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-Worl..
AQ
07/29EISAI : Biogen, Eisai report design of real-world study of Alzheimer's treatment
RE
07/29EISAI : Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially ..
AQ
07/28Bristol Myers sees return to growth for Opdivo, tops estimates
RE
07/27EISAI : Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at A..
PU
07/26EISAI : Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzhei..
AQ
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combination for Pa..
AQ
07/22EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Pa..
AQ
07/21Eisai to present latest data on pipeline assets in the area of alzheimer's disease and ..
AQ
07/21BIOGEN : Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage
RE
07/21EISAI : To present latest data on pipeline assets in the area of alzheimer's disease and d..
PU
07/20EISAI : to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and D..
AQ
07/19EISAI : Status of aduhelm in the united states
AQ
07/19EISAI : Launches bile acid transporter inhibitor goofice® in thailand
PU
07/19EISAI : STATUS OF ADUHELM™ IN THE UNITED STATES
PU
07/18EISAI : Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
AQ
07/16Nikkei dips below 28,000 as tech stocks track Nasdaq slide
RE
07/15Nikkei breaks below 28,000 as tech stocks track Nasdaq slide
RE
07/12Japanese shares rebound on growth confidence, Yaskawa's outlook
RE
07/09BIOGEN : FDA Approves Updated ADUHELM Prescribing Information to Emphasize Population Stud..
AQ
07/09Japanese shares fall to 8-week low on growth slowdown worries
RE
07/09BIOARCTIC : Interim Report for the period April - June 2021
AQ
07/08Japanese shares eye worst week in nearly 1 year on economic slowdown concerns
RE
07/08BIOGEN : Eisai Receives FDA Approval for Updated Label of Alzheimer's Drug Aduhelm
MT
06/30EISAI : Launches in-house developed anti-insomnia drug dayvigo (lemborexant) in hong kong
AQ
06/30EISAI : Launches in-house developed anti-insomnia drug dayvigo® (lemborexant) in hong kong..
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on EISAI CO., LTD.